Investigational Drug Information for RDEA3170
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for RDEA3170?
RDEA3170 is an investigational drug.
There have been 16 clinical trials for RDEA3170.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 1st 2013.
The most common disease conditions in clinical trials are Gout, Hyperuricemia, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Ardea Biosciences, Inc., AstraZeneca, and Clinical Laboratory: USA.
There are fourteen US patents protecting this investigational drug and one hundred and ninety-eight international patents.
Summary for RDEA3170
| US Patents | 14 |
| International Patents | 198 |
| US Patent Applications | 44 |
| WIPO Patent Applications | 31 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 2 (2013-08-01) |
| Vendors | 35 |
Recent Clinical Trials for RDEA3170
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia | AstraZeneca | Phase 2 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA | Analytical Laboratory (Pharmacokinetic Sample Analysis): USA | Phase 2 |
| A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA | Clinical Laboratory: USA | Phase 2 |
Clinical Trial Summary for RDEA3170
Top disease conditions for RDEA3170
Top clinical trial sponsors for RDEA3170
US Patents for RDEA3170
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RDEA3170 | See Plans and Pricing | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | ARDEA BIOSCIENCES, INC. (San Diego, CA) | See Plans and Pricing |
| RDEA3170 | See Plans and Pricing | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | See Plans and Pricing |
| RDEA3170 | See Plans and Pricing | Condensed ring derivative, and preparation method, intermediate, pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (Shanghai, CN) | See Plans and Pricing |
| RDEA3170 | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| RDEA3170 | See Plans and Pricing | URAT1 inhibitor | Nippon Chemiphar Co., Ltd. (Tokyo, JP) J-Pharma Co., Ltd. (Kanagawa, JP) DeThree Res. Lab. Inc. (Ibaraki, JP) | See Plans and Pricing |
| RDEA3170 | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RDEA3170
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RDEA3170 | Australia | AU2012332154 | 2031-11-03 | See Plans and Pricing |
| RDEA3170 | Brazil | BR112014010495 | 2031-11-03 | See Plans and Pricing |
| RDEA3170 | Canada | CA2852490 | 2031-11-03 | See Plans and Pricing |
| RDEA3170 | China | CN104023723 | 2031-11-03 | See Plans and Pricing |
| RDEA3170 | China | CN106963761 | 2031-11-03 | See Plans and Pricing |
| RDEA3170 | Denmark | DK2776028 | 2031-11-03 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
